AIM: To investigate serum levels of soluble CD146(s CD146) and vascular endothelial growth factor receptor 2(VEGFR2) in patients with age-related macular degeneration(AMD). METHODS: Eighty-eight patients with exudativ...AIM: To investigate serum levels of soluble CD146(s CD146) and vascular endothelial growth factor receptor 2(VEGFR2) in patients with age-related macular degeneration(AMD). METHODS: Eighty-eight patients with exudative AMD and 45 sex-and age-matched healthy controls were enrolled in this study conducted in China. Serum samples was obtained from the patients with exudative AMD and from the controls. Serum sCD146 and VEGFR2 protein levels were measured using an enzyme-linked immunosorbent assay.RESULTS: We found that serum sCD146 and VEGFR2 protein levels were significantly higher in the patients with exudative AMD group than in the controls(t=3.859, P<0.001 and t=3.829, P<0.001, respectively). Serum sCD146 levels were significantly higher in patients with classic choroidal neovascularization(CNV) than in those with occult CNV(t=9.899, P<0.001). There was a significant difference in the trend for exudative AMD in the highest versus lowest quartile of circulating sCD146 levels(χ2=10.29, P=0.001). The receiver operating characteristic curve analysis showed that the area under the curve was 0.696 for s CD146(95%CI: 0.601-0.791) with an optimum diagnostic cut-off value of 157.16 ng/mL, a sensitivity of 55.7%, and a specificity of 82.2%.CONCLUSION: The serum sCD146 level increases and may be a biomarker for exudative AMD.展开更多
基金Supported by the National Natural Science Foundation of China(No.81670881)
文摘AIM: To investigate serum levels of soluble CD146(s CD146) and vascular endothelial growth factor receptor 2(VEGFR2) in patients with age-related macular degeneration(AMD). METHODS: Eighty-eight patients with exudative AMD and 45 sex-and age-matched healthy controls were enrolled in this study conducted in China. Serum samples was obtained from the patients with exudative AMD and from the controls. Serum sCD146 and VEGFR2 protein levels were measured using an enzyme-linked immunosorbent assay.RESULTS: We found that serum sCD146 and VEGFR2 protein levels were significantly higher in the patients with exudative AMD group than in the controls(t=3.859, P<0.001 and t=3.829, P<0.001, respectively). Serum sCD146 levels were significantly higher in patients with classic choroidal neovascularization(CNV) than in those with occult CNV(t=9.899, P<0.001). There was a significant difference in the trend for exudative AMD in the highest versus lowest quartile of circulating sCD146 levels(χ2=10.29, P=0.001). The receiver operating characteristic curve analysis showed that the area under the curve was 0.696 for s CD146(95%CI: 0.601-0.791) with an optimum diagnostic cut-off value of 157.16 ng/mL, a sensitivity of 55.7%, and a specificity of 82.2%.CONCLUSION: The serum sCD146 level increases and may be a biomarker for exudative AMD.
文摘目的：探讨2型糖尿病患者血清铁调素（Hepcidin）、铁蛋白（SF）、转铁蛋白受体（sTfR）和血清铁（SI）的变化与临床意义。方法130例2型糖尿病患者，分为两组，A 组为微量蛋白尿组45例（mAlb30-300 mg／24 h），B 组为正常蛋白尿组85例（mAlb＜30 mg／24 h），另选同期45例健康体检者为对照 C 组。各组均取空腹晨血5 ml 离心取血清检测铁调素，SF，sTfR 和 SI 含量。结果A 组患者血清铁调素和 SF 水平（42.27±32.12 ng／ml，211.6±107.2 ng／ml）均显著高于B 组（26.12±18.36 ng／ml，179.1±109.7 ng／ml；P 均＜0.05）和 C 组（9.47±1.65 ng／ml，84.41±47.10 ng／ml），（P 均＜0.01）；B 组患者铁调素和 SF 水平显著高于 C 组（P 均＜0.01）。各组之间 SI 水平（15.26μmol／L，18.65μmol／L，17.71μmol／L）和 sTfR 水平（1.12μg／L，1.05μg／L，1.16μg／L）差异均无统计学意义（t ＝0.469-1.176，P 均＞0.05）。相关分析显示，2型糖尿病患者铁调素与 SF 呈显著正相关（r＝0.329，P ＜0.05），铁调素与 sTfR，SI 无显著相关性（r＝0.169，P ＞0.05；r＝－0.149，P ＞0.05）。结论2型糖尿病患者体内存在以血清铁调素、SF 增高为主的铁超负荷和铁代谢紊乱，并与尿微量清蛋白的排泄呈正相关。因此，检测血清铁调素和 SF 可作为糖尿病早期肾功能损伤的重要预测因子。
